Anisotropy measurements in air and in polystyrene were performed for a Nucletron microSelectron 10 Ci Ir-192 source. TLD rods of similar sensitivity (+/- 3%) were placed on a semicircle around the source center which had been precisely localized by either radiographic means or direct measurement. The anisotropy, expressed as a ratio of TLD reading at a given angle relative to the longitudinal source axis, over the reading at 90 degrees, was measured for distances between 1 and 10 cm from the source center. For both media, a marked anisotropy of the high dose rate source was found. In air, there is no detectable variation in anisotropy with distance up to 10 cm from the source. In polystyrene, however, the anisotropy becomes less pronounced with increasing distance due to scatter. For both media, no difference, within the estimated experimental accuracy of +/- 5%, was found between three consecutive sources installed by the vendor.

SUMMARY The purpose of this investigation was to examine changes in pretreatment prostate-specific antigen (PSA), stage, and grade over the past decade as a function of race and geographic region. A multiinstitutional database representing 6,790 patients (1,417 African-American, 5,373 white) diagnosed with nonmetastatic prostate cancer between 1988 and 1997 was constructed. PSA, stage, and grade data were tabulated by calendar year and region, and time trend analyses based on race and region were performed. There was an overall decline of PSA of 0.8%/year, which was significant (P = 0.0001), with a faster rate of decline in African-Americans (1.9%/year) than for whites (0.6%/year). The odds ratio (OR) for a stage shift was 1.09, which was significant (P < 0.0001), and this shift was greater in whites. The OR for an overall grade shift was 1.15, which was significant (P < 0.0001). Although grade and PSA trends were similar for the different regions, there were significant regional differences in stage trends. The implications are that the face of prostate cancer has changed over the past decade; i.e., the distributions of stage, grade, and PSA (the most important prognosticators) have changed. In addition, the countenances of that face are different for whites and African-Americans. For African-Americans, this is good news: the stage, grade, and PSA distributions are more favorable now than before. For whites, the trends are more complex and more dependent on region. These

Quantitative information on photon scattering around brachytherapy sources is needed to develop dose calculation formalisms capable of predicting dosimetric parameters with minimal empiricism. Photon absorption and scatter around brachytherapy sources can be characterized using the tissue attenuation factor, defined as the ratio of dose in water to water kerma in free space. In this study, the tissue attenuation factor along two major axes of a high dose rate (HDR) 192Ir source was determined by TLD measurements and MCNP Monte Carlo calculations. A calculational method is also suggested to derive the tissue attenuation factor along the longitudinal source axis from the factor along the transverse axis, using published anisotropy data as input. TLD and Monte Carlo results agreed with each other for both source axes within the statistical uncertainty (approximately +/- 5%) of Monte Carlo calculations. Comparison with published data, available only for the transverse source axis, also showed good agreement within +/- 5%. The shape and magnitude of the tissue attenuation factor are found to be remarkably different between the two axes. The tissue attenuation factor reaches a maximum value of about 1.4 at 8 cm from the source along the longitudinal source axis, while a maximum value of about 1.04 occurs at 3-4 cm from the source along the transverse axis. The calculated tissue attenuation factor along the longitudinal source axis generally reproduced the TLD and Monte Carlo results within +/- 5% at most radial distances.

Reduction in unwanted scatter dose to the contralateral breast is in accord with the philosophy of keeping radiation exposure as low as reasonably achievable and might be of most benefit for young patients.

Thermoluminescent dosimeters (TLDs) were used to measure scatter radiation to the uninvolved breast in 30 patients who received tangential breast or chest-wall radiation with a technique in which the deep edges of the tangential fields were aligned. In most patients, measurements were made during the 1st week of radiation therapy, after port radiographs were obtained to ensure proper field position and accurate alignment of the posterior tangential field edges. Phantom measurements were made simultaneously with TLD measurements to systematically assess the scatter dose as a function of the wedging, number of fields, type of accelerator, beam energy, and bolus used in each treatment. For most patients, the scatter dose to the contralateral breast at a point on the skin 5 cm outside the edge of the medial beam was 8%-13% of the prescribed dose. However, higher doses (up to 36% of the therapeutic dose) were recorded in some patients.